A phase 4 clinical trial called REMODEL has found that weekly dupilumab injections meaningfully improve esophageal distensibility — essentially, how well the esophagus can stretch — in adults with active eosinophilic esophagitis (EoE). The findings were presented at the American College of Gastroenterology's Annual Scientific Meeting in Nashville on October 12, 2026.

The trial enrolled 69 adults randomized 2:1 to receive either 300 mg of dupilumab weekly or placebo for 24 weeks. Researchers measured changes in the narrowest fixed diameter of the distal esophagus and tracked endoscopic reference scores (EREFS) as a secondary endpoint. Dupilumab was described as "generally well-tolerated" throughout the study.

Notably, patients with a lower baseline esophageal diameter (under 17 mm) showed even more pronounced improvements, suggesting the drug works across both the fibrostenotic and inflammatory ends of the EoE spectrum.

By the Numbers:

• 1.28 mm improvement in esophageal distensibility plateau (DP) diameter in the dupilumab group vs. placebo
• 69 adults enrolled; randomized 2:1 (dupilumab vs. placebo)
• 24 weeks of treatment assessed; phase 2 data showed efficacy as early as 12 weeks

Why it matters: EoE can cause painful swallowing and food impaction, and improving esophageal flexibility is a key treatment goal. These results reinforce dupilumab's role as an effective therapy across the full disease spectrum, potentially reducing the need for repeated esophageal dilations.